Anavex Life Sciences Future Growth
Future criteria checks 3/6
Anavex Life Sciences is forecast to grow earnings and revenue by 43.9% and 50.6% per annum respectively while EPS is expected to grow by 51.2% per annum.
Key information
43.9%
Earnings growth rate
51.2%
EPS growth rate
| Biotechs earnings growth | 27.6% |
| Revenue growth rate | 50.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 23 Dec 2024 |
Recent future growth updates
Recent updates
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
Dec 25
Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis
Dec 24Anavex: EU Approval Application Is A Precipitous Moment
Dec 08Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease
Nov 11Anavex: Understanding Their Latest Alzheimer's Data News With Caution
Nov 05Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)
Oct 08Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising
Jul 29Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Jul 17Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Apr 01Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Sep 19We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
May 10Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth
Jan 16We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Oct 01Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia
Sep 19Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease
Sep 07Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01
Aug 09We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Jun 17Anavex: Increasing Shareholder Value Against All Odds
May 31Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease
Mar 23We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn
Mar 03Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease
Feb 09Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity
Feb 02Anavex: 2022 Has Major, Pivotal Catalysts
Jan 17Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Nov 16Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?
Nov 05Anavex Life Sciences: Still Room To Run
Aug 29Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Jul 30Anavex: A Catalyst-Rich Year
Jul 05Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers
Jun 21Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease
Jun 14Anavex Life's late-stage ANAVEX2-73 study in Alzheimer’s exceeds target enrollment
Jun 08Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2027 | 543 | 360 | 822 | 610 | 2 |
| 9/30/2026 | 334 | 453 | 542 | 738 | 2 |
| 9/30/2025 | N/A | 80 | -60 | 222 | 3 |
| 9/30/2024 | N/A | -43 | -31 | -31 | N/A |
| 6/30/2024 | N/A | -42 | -30 | -30 | N/A |
| 3/31/2024 | N/A | -41 | -32 | -32 | N/A |
| 12/31/2023 | N/A | -43 | -29 | -29 | N/A |
| 9/30/2023 | N/A | -48 | -28 | -28 | N/A |
| 6/30/2023 | N/A | -52 | -26 | -26 | N/A |
| 3/31/2023 | N/A | -53 | -25 | -25 | N/A |
| 12/31/2022 | N/A | -50 | -27 | -27 | N/A |
| 9/30/2022 | N/A | -48 | -24 | -24 | N/A |
| 6/30/2022 | N/A | -45 | -28 | -28 | N/A |
| 3/31/2022 | N/A | -43 | -28 | -28 | N/A |
| 12/31/2021 | N/A | -41 | -26 | -26 | N/A |
| 9/30/2021 | N/A | -38 | -30 | -30 | N/A |
| 6/30/2021 | N/A | -32 | -29 | -29 | N/A |
| 3/31/2021 | N/A | -28 | -25 | -25 | N/A |
| 12/31/2020 | N/A | -28 | -23 | -23 | N/A |
| 9/30/2020 | N/A | -26 | -21 | -21 | N/A |
| 6/30/2020 | N/A | -26 | -18 | -18 | N/A |
| 3/31/2020 | N/A | -26 | -21 | -21 | N/A |
| 12/31/2019 | N/A | -26 | -20 | -20 | N/A |
| 9/30/2019 | N/A | -26 | -19 | -19 | N/A |
| 6/30/2019 | N/A | -26 | -20 | -20 | N/A |
| 3/31/2019 | N/A | -23 | -15 | -15 | N/A |
| 12/31/2018 | N/A | -20 | -13 | -13 | N/A |
| 9/30/2018 | N/A | -17 | -13 | -13 | N/A |
| 6/30/2018 | N/A | -17 | N/A | -11 | N/A |
| 3/31/2018 | N/A | -18 | N/A | -12 | N/A |
| 12/31/2017 | N/A | -14 | N/A | -9 | N/A |
| 9/30/2017 | N/A | -13 | N/A | -9 | N/A |
| 6/30/2017 | N/A | -15 | N/A | -9 | N/A |
| 3/31/2017 | N/A | -13 | N/A | -8 | N/A |
| 12/31/2016 | N/A | -14 | N/A | -9 | N/A |
| 9/30/2016 | N/A | -15 | N/A | -9 | N/A |
| 6/30/2016 | N/A | -14 | N/A | -9 | N/A |
| 3/31/2016 | N/A | -16 | N/A | -8 | N/A |
| 12/31/2015 | N/A | -15 | N/A | -7 | N/A |
| 9/30/2015 | N/A | -12 | N/A | -4 | N/A |
| 6/30/2015 | N/A | -15 | N/A | -4 | N/A |
| 3/31/2015 | N/A | -12 | N/A | -3 | N/A |
| 12/31/2014 | N/A | -11 | N/A | -3 | N/A |
| 9/30/2014 | N/A | -10 | N/A | -3 | N/A |
| 6/30/2014 | N/A | -5 | N/A | -2 | N/A |
| 3/31/2014 | N/A | -4 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVXL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: AVXL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AVXL is expected to become profitable in the next 3 years.
Revenue vs Market: AVXL is forecast to have no revenue next year.
High Growth Revenue: AVXL is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AVXL's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:13 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Anavex Life Sciences Corp. is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Caroline Palomeque | Berenberg |
| Yun Zhong | BTIG |
| Charles Duncan | Cantor Fitzgerald & Co. |